Italy seeks 1.2 bn euros in anti-trust damages from Roche, Novartis

Italy's health ministry is seeking 1.2 billion euros ($1.6 million) in compensation from Swiss pharma giants Novartis and Roche for the manipulation of sales of a cheap drug used to treat eye problems, Italian media reported Wednesday.

The ministry's move came after Italy's antitrust body fined the two firms 182.5 million euros over their "illicit deal to prevent the use of a very cheap drug, Avastin, in treating" sight problems.

The antitrust body said the two pharma giants had colluded with the aim of boosting the sales of a more expensive product, Lucentis. It also claimed that they steered health services and doctors away from Avastin by describing it as more dangerous.

Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as .

Novartis has rejected the anti-competition accusations and has said it would appeal against the fine.

add to favorites email to friend print save as pdf

Related Stories

Novartis tries to make UK hospitals use $1000 drug

Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

FDA warns of another compounding pharmacy recall

Mar 20, 2013

(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Japan prosecutors raid Novartis over drug ad scandal

Feb 19, 2014

Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Recommended for you

Physicians warned about counterfeit medical devices

2 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

2 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

15 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

User comments